BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I. Literature review of the distribution of hepatitis C virus genotypes across Europe: HCV Genotype Distribution in Europe Review. J Med Virol 2016;88:2157-69. [DOI: 10.1002/jmv.24573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
2 Minosse C, Salichos L, Taibi C, Luzzitelli I, Nardozi D, Capobianchi MR, D'Offizi G, McPhee F, Garbuglia AR. Phylogenetic and Phylodynamic Analyses of HCV Strains Circulating among Patients Using Injectable Drugs in Central Italy. Microorganisms 2021;9:1432. [PMID: 34361868 DOI: 10.3390/microorganisms9071432] [Reference Citation Analysis]
3 Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Reference Citation Analysis]
4 Akaberi D, Bergfors A, Kjellin M, Kameli N, Lidemalm L, Kolli B, Shafer RW, Palanisamy N, Lennerstrand J. Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach. Infect Ecol Epidemiol 2018;8:1528117. [PMID: 30319736 DOI: 10.1080/20008686.2018.1528117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. Eur J Gastroenterol Hepatol 2018;30:302-9. [PMID: 29271782 DOI: 10.1097/MEG.0000000000001035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sebastiani M, Milazzo L, Atzeni F, Vacchi C, Manfredi A, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, D'Angelo S, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Foppa CU, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-Puttini P, Galli M. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. Mod Rheumatol 2019;29:895-902. [PMID: 30582388 DOI: 10.1080/14397595.2018.1558918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Alberti A, Angarano G, Colombo M, Craxì A, Di Marco V, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P. Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. Clin Res Hepatol Gastroenterol 2019;43:190-200. [PMID: 30377096 DOI: 10.1016/j.clinre.2018.09.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 2019;54:1042-50. [PMID: 31424972 DOI: 10.1080/00365521.2019.1652846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of hepatitis C virus genotypes in Istanbul, Turkey. Indian J Med Microbiol 2018;36:192-6. [PMID: 30084409 DOI: 10.4103/ijmm.IJMM_17_381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Bouacida L, Suin V, Hutse V, Boudewijns M, Cartuyvels R, Debaisieux L, De Laere E, Hallin M, Hougardy N, Lagrou K, Oris E, Padalko E, Reynders M, Roussel G, Senterre JM, Stalpaert M, Ursi D, Vael C, Vaira D, Van Acker J, Verstrepen W, Van Gucht S, Kabamba B, Quoilin S, Muyldermans G. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018;13:e0207584. [PMID: 30517127 DOI: 10.1371/journal.pone.0207584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Rossetti B, Bai F, Tavelli A, Galli M, Antinori A, Castelli F, Pellizzer G, Cozzi-Lepri A, Bonora S, Monforte AD, Puoti M, De Luca A; ICONA Foundation study group. Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect 2018;24:422-7. [PMID: 28765078 DOI: 10.1016/j.cmi.2017.07.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
13 Wahid B, Waqar M, Rasool N, Rehman Z, Saeed J, Wasim M, Khan MA, Ali A, Rafique S, Sajjad, Idrees M. Recent trends in molecular epidemiology of Hepatitis C virus in Mardan, KPK Pakistan. Infect Genet Evol 2018;66:66-71. [PMID: 30201500 DOI: 10.1016/j.meegid.2018.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
15 Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Ups J Med Sci 2018;123:50-6. [PMID: 29536805 DOI: 10.1080/03009734.2018.1441928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]